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OBJECTIVE—The effect of diabetes on mild cognitive impair-
ment (MCI) and its conversion to dementia remains controver-
sial. We sought to examine whether diabetes and pre-diabetes
are associated with MCI and accelerate the progression from
MCI to dementia.
RESEARCH DESIGN AND METHODS—In the Kungsholmen
Project, 963 cognitively intact participants and 302 subjects with
MCI (120 with amnestic MCI [aMCI ] and 182 with other cognitive
impairment no dementia [oCIND]) age 75 years were identiﬁed
at baseline. The two cohorts were followed for 9 years to detect
the incident MCI and dementia following international criteria.
Diabetes was ascertained based on a medical examination,
hypoglycemic medication use, and random blood glucose level
11.0 mmol/l. Pre-diabetes was deﬁned as random blood glucose
level of 7.8–11.0 mmol/l in diabetes-free participants. Data were
analyzed using standard and time-dependent Cox proportional-
hazards models.
RESULTS—During the follow-up period, in the cognitively in-
tact cohort, 182 people developed MCI (42 aMCI and 140 oCIND),
and 212 developed dementia. In the MCI cohort, 155 subjects
progressed to dementia, the multi-adjusted hazard ratio (95% CI)
of dementia was 2.87 (1.30–6.34) for diabetes, and 4.96 (2.27–
10.84) for pre-diabetes. In a Kaplan-Meier survival analysis,
diabetes and pre-diabetes accelerated the progression from MCI
to dementia by 3.18 years. Diabetes and pre-diabetes were
neither cross-sectionally nor longitudinally associated with MCI.
CONCLUSIONS—Diabetes and pre-diabetes substantially ac-
celerate the progression from MCI to dementia, and anticipate
dementia occurrence by more than 3 years in people with MCI.
The association of diabetes with the development of MCI is less
evident in old people. Diabetes 59:2928–2935, 2010
T
he impact of diabetes on cognitive function has
been addressed in several studies showing that
type 2 diabetes is associated with cognitive
decline in aging (1). Furthermore, many large
population-based longitudinal studies have demonstrated
an increased risk of dementia in people with diabetes (2),
but the association of diabetes with Alzheimer’s disease is
less evident in some studies (2,3). Overall, diabetes leads
to a 20–70% greater decline in cognitive performance, and
a 60% higher risk of dementia (4). Even pre-diabetes, the
condition of impaired glucose regulation, has been related
to cognitive decline and an increased risk of dementia
(5,6), although a cross-sectional study found no associa-
tion of impaired fasting blood glucose with cognitive
function (7). In addition, three studies addressing the
relation between diabetes and mild cognitive impairment
(MCI) have also shown conﬂicting results (8–10).
MCI represents the usual transitional phase from normal
cognitive function to dementia, although not all people
with MCI will develop dementia (11). Different criteria and
subdivisions of MCI have been proposed and modiﬁed
over time (12). MCI has been subdivided into two major
forms—amnestic MCI (aMCI) and other domain cognitive
impairment no dementia (oCIND) (13–15). Progression to
clinically diagnosable dementia occurs at a higher rate
from MCI than from unimpaired cognition; the estimated
rate of conversion is approximately 30% over 3 years (16).
However, the extent to which diabetes accelerates this
progression is unclear. Only two population-based studies
have addressed this issue and both showed nonsigniﬁcant
effect of diabetes on the conversion from MCI to dementia
(10,17).
Most studies that have addressed the association of
diabetes with dementia included people with MCI at
baseline assessment as nondemented and people with
pre-diabetes with a nondiabetic group. These studies may
underestimate the risk of dementia associated with diabe-
tes. We have demonstrated that diabetes and pre-diabetes
increase the risk of dementia and its main subtypes
(5,18–20). In the present study, we sought to investigate
the association of diabetes and pre-diabetes with the risk
of MCI and to verify the hypothesis that diabetes and
pre-diabetes may accelerate the progression from MCI to
dementia.
RESEARCH DESIGN AND METHODS
Study population. Data were derived from the Kungsholmen Project, which
was a population-based prospective cohort study on aging and dementia,
including all registered inhabitants who were age 75 years and living in the
Kungsholmen district of central Stockholm, Sweden, in 1987 (21,22). By
means of a two-phase survey, among the 1,700 participants at baseline
(1987–1989), two cohorts (a cognitively intact cohort and an MCI cohort) were
identiﬁed. The two cohorts were followed for 9 years (until 1997–1998) to
detect incident dementia and MCI cases.
Cognitively intact cohort. The cognitively intact cohort consisted of 1,098
individuals after excluding 225 persons who were clinically diagnosed with
prevalent dementia (using Diagnostic and Statistical Manual of Mental
Disorders, Revised Third Edition [DSM-III-R] criteria) (23), 31 subjects with
very low global cognitive status in the absence of a dementia diagnosis, and 9
with unknown educational level. An additional 337 subjects who were
identiﬁed as having prevalent MCI (14,24) constituted the MCI cohort. Of the
1,098 cognitively intact individuals, 135 dropped out at the ﬁrst follow-up
examination resulting in 963 participants.
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ﬁrst follow-up examination or had moved, leaving 302 persons for the MCI
cohort. This cohort included 120 aMCI subjects who had memory complaints
and objective episodic memory impairment (14,24) and 182 oCIND subjects
who had signiﬁcant impairment in global cognitive performance, as deﬁned in
a previous report (15).
During the 9-year follow-up, three clinical examinations were carried out at
an average interval of 3 years. Throughout the follow-up period, in the
cognitively intact cohort, 357 people died and 52 dropped out. In the MCI
cohort, 101 individuals died, and 13 were dropouts. Figure 1 shows the details
of a ﬂowchart of the study population from baseline to the third follow-up
examination (1987–1989 to 1997–1998).
Medical records and death certiﬁcates were available for all participants
who died during the follow-up. Informed consent was received from partici-
pants or from informants when the person was cognitively impaired. The
Ethics Committee at Karolinska Institutet approved all phases of the Kung-
sholmen Project.
Data collection. Global cognitive functioning was assessed with the Mini-
Mental State Examination (MMSE), and subjective memory problems were
evaluated by questioning the subjects and close informants. Data on age, sex,
and education were collected from subjects at baseline following standardized
protocols (22,25). Education was measured as the maximum years of formal
schooling, and was dichotomized (8 vs. 8 years) based on results from a
previous study (26). Weight and height were measured with a standard scale
in light clothing and with no shoes. BMI was calculated as weight (kg) divided
by height (m) squared. Arterial blood pressure (i.e., systolic Korotkoff phase
I and diastolic phase V) was measured on the right arm by nurses, with the
subject placed in a sitting position after a 5-min rest. Information on medical
history was taken for all participants from the inpatient registry system, which
encompasses all hospitals in Stockholm from 1969 onward. The International
Classiﬁcation of Disease, 8th revision (ICD-8) and the ICD-9th revisions
(ICD-9) were used in the registry system until 1997. Medical conditions
derived from the inpatient register database included ischemic heart disease
(ICD-8, ICD-9, codes 410–414), heart failure or left ventricular failure or other
myocardial insufﬁciency (ICD-8. codes 427 and 428; ICD-9, code 428.x), atrial
ﬁbrillation (ICD-8 code 427.9; ICD-9 code 427), stroke (ICD-8, ICD-9, codes
430–438), hypertension (ICD-8 codes 400–404; ICD-9 codes 401–405), and
diabetes (ICD-8, ICD-9. code 250). Information on medical drug use for the 2
weeks prior to the baseline interview was collected from the subjects. Drugs
were coded according to the Anatomical Therapeutic Chemical (ATC) Clas-
siﬁcation System (27). Hypoglycemic drugs included hypoglycemic medica-
tions or insulin injection (ATC code A10). Blood pressure lowering drugs were
deﬁned as all medicines potentially used for lowering blood pressure (ATC
codes C02, C03, and C07). Genomic DNA was prepared from peripheral blood
samples that were taken at baseline, and APOE allelic status was determined
following a standard procedure (28).
Assessment of diabetes and pre-diabetes. Blood samples were taken at
baseline survey and at each follow-up examination. Random (nonfasting)
blood glucose was measured using a glucose oxidase procedure at baseline
and follow-ups. Diabetes was identiﬁed by clinical examination and through
1,700 participants (phase I) aged  75 years in October 1987 
35 refused or moved 
1,435 nondemented participants identified (phase II) 
225 prevalent dementia; 31 MMSE<20;   
9 missing data on education 
   Baseline survey 
    1987-1989 
3
rd follow-up 
1997-1998 
2
nd follow-up 
1994-1996 
302 MCI (182 oCIND;120 aMCI) at baseline   
337 MCI (206 oCIND; 131 aMCI) 
222 examined: 93 
dementia  
1
st follow-up 
1991-1993 
80 deceased: 15 
dementia  
8 refused or moved 
121 dementia-free at the 1
st follow-up 
81 examined: 26 
dementia  
40 deceased: 4 
dementia  
5 refused or moved 
50 dementia-free at the 2
nd follow-up 
40 examined: 17 
dementia  
10 deceased 
1,098 participants cognitively intact 
963 cognitively intact at baseline 
 
  540 cognitively intact at the 1
st follow-up 
  278 cognitively intact at the 2
nd follow-up 
764 examined: 67 oCIND; 
27 aMCI; 96 dementia 
424 examined: 53 oCIND; 
13 aMCI; 62 dementia 
216 examined:19 oCIND; 
 2 aMCI; 34 dementia 
  135 refused or moved
199 deceased: 
7 dementia  
  34 refused or moved
62 deceased: 
6 dementia  
116 deceased: 
7 dementia  
  18 refused or moved
FIG. 1. Flowchart of the study population in the Kungsholmen Project.
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glucose level 11.0 mmol/l (19,29). Pre-diabetes was considered to be present
if random blood glucose level was 7.8–11.0 mmol/l in diabetes-free partici-
pants (5,29).
Deﬁnition of mild cognitive impairment. People with MCI included all
nondemented participants who fulﬁlled aMCI or oCIND criteria. Amnestic
MCI is characterized by memory deﬁcits, and was deﬁned according to
standard criteria (24,30) and operationalized as follows (15): 1) absence of
dementia; 2) normal general cognitive function: absence of oCIND; 3) memory
complaints: self- or informant-reported memory problems; 4) objective mem-
ory impairment: scoring 1.5 SD below age- and education-adjusted mean in a
verbal episodic memory test (free recall of rapidly presented random words)
(31); and 5) normal activities of daily living (ADL): no impairment in the Katz
ADL scale. A diagnosis of oCIND represents global cognitive impairment, and
was deﬁned as having no dementia and scoring 1 SD or more below age- and
education-adjusted means on the MMSE derived from the dementia-free
sample at baseline (15,32). A diagnosis of oCIND was applied to subjects who
were considered neither as normal nor as aMCI nor as demented. In the
present study, aMCI and oCIND were mutually exclusive.
Diagnosis of dementia. At baseline and follow-up, all participants under-
went a comprehensive medical and cognitive assessment. Cognitive functions
were tested by asking for facts of general knowledge and past personal
information (semantic and episodic memory); by object naming and compre-
hension of commands and sentences (language); by problem solving and
interpretation of proverbs (abstract thinking); by coping ﬁgures (visuospatial
ability); and by calculation and solving mathematical problems (calculation).
Dementia was diagnosed on the basis of clinical judgment following DSM-III-R
criteria, in which a validated 3-step diagnostic procedure was used (22). Two
examining physicians independently made a preliminary diagnosis, and in the
case of disagreement, a third opinion was sought to reach a concordant
diagnosis. The diagnosis of Alzheimer’s disease (AD) required gradual onset,
progressive deterioration, and lack of any other speciﬁc causes of dementia.
The diagnosis of vascular dementia (VaD) required abrupt onset, stepwise
deterioration, history of stroke, or focal deﬁcits. The Hachinski scale was also
used to support the differential diagnosis between AD and VaD (33). The
diagnostic criteria for AD and VaD were equivalent to probable AD according
to the National Institute of Neurological and Communicative Disorders and
Stroke-Alzheimer’s Disease and Related Disorders Association (NINCDS-
ADRDA) criteria (34), and to the National Institute of Neurological Disorders
and Stroke Association Internationale pour la Recherche et l’Enseignement en
Neurosciences (NINDS-AIREN) criteria (35). For deceased participants, the
diagnosis of dementia and its subtypes was made by two physicians by
reviewing the medical records and death certiﬁcates.
Statistical analysis. The baseline characteristics of people with diabetes and
pre-diabetes and participants free from these conditions were compared using

2 tests for categorical variables and one-way ANOVAs for continuous
variables. For the cross-sectional data at baseline, logistic regression analyses
were used to estimate the odds ratio (OR) and 95% conﬁdence intervals (CIs)
of MCI, aMCI, and oCIND separately in relation to diabetes and pre-diabetes
in the dementia-free participants.
The incidence rates were calculated as the number of events occurring
during the entire follow-up period divided by person-years of follow-up
standardized by age, sex, and education. Cox proportional hazards models
were used to estimate the hazard ratios (HRs) and 95% CIs of dementia, AD,
and MCI in relation to diabetes and pre-diabetes. Diabetes and pre-diabetes
were modeled as separate and combined groups in the analyses. For nonde-
mented subjects in the MCI cohort and non-MCI participants in the cognitively
intact cohort, the follow-up time was calculated from the date of baseline
interview to the date of the last follow-up examination or death. For the
demented and MCI cases, the follow-up time was estimated as the full time
during which the subjects were free of dementia or MCI plus half of the follow-up
time during which dementia or MCI developed.
The proportional hazards assumption was conﬁrmed by graphs and tests
based on Schoenfeld residuals. Age, sex, education, baseline MMSE score,
BMI, APOE genotype, and vascular disorders (i.e., heart disease, stroke,
antihypertensive drug use, and blood pressure) were considered as potential
confounders. As diabetes and pre-diabetes are related to elevated mortality,
we also adjusted for survival status at follow-up (20). All dementia, AD, MCI,
aMCI, oCIND, and death were used as separate outcomes in the Cox
regression analyses. The Kaplan-Meier survival analysis was used to compare
the cumulative probability of events among subjects in different groups. In
secondary analyses, we modeled diabetes and pre-diabetes as time-dependent
covariates. The statistical analyses were performed using Stata SE 10 for
Windows (StataCorp, College Station, TX).
RESULTS
Cross-sectional relationship between diabetes and
MCI. Among the 1,435 dementia-free participants at base-
line, 337 were detected as MCI cases, including 131 aMCI
and 206 oCIND. Compared with non-MCI subjects, people
with MCI were older (OR 0.94, [95% CI 0.89–0.99, P 
0.015]), and had a lower level of education (8 vs. 8
years, OR 2.13 [95% CI 1.35–3.38]) and MMSE score (OR
0.36 [95% CI 0.29–0.46]), and higher proportion of APOE
ε 4 carriers (OR 1.91 [95% CI 1.15–3.15]). The two groups
showed no signiﬁcant differences in terms of sex, stroke,
heart disease, and blood pressure. Logistic regression
analyses were performed to assess the cross-sectional
relationship between diabetes and MCI based on the
dementia-free subjects (n  1,435). The multi-adjusted
ORs related to diabetes or pre-diabetes were 1.32 (95% CI
0.82–1.31) for overall MCI, 1.12 (95% CI 0.67–1.20) for
aMCI, and 1.03 (95% CI 0.57–1.23) for oCIND.
Nonparticipants of the follow-up. Of the 1,435 individ-
uals who were initially identiﬁed as free of dementia at
baseline, 170 subjects were lost to the ﬁrst follow-up (Fig.
1). Compared with participants, dropouts were younger,
but the two groups had no signiﬁcant differences in other
features. Multiple logistic regression analysis showed that
being a dropout had ORs of 0.94 (95% CI 0.91–0.98) for old
age, 1.26 (95% CI 0.84–1.87) for female sex, 1.24 (95% CI
0.89–1.73) for low education, 1.02 (95% CI 0.94–1.09) for a
lower score on MMSE (24 vs. 24), 0.35 (95% CI
0.28–1.06) for diabetes, 0.69 (95% CI 0.47–1.09) for heart
disease, and 0.66 (95% CI 0.45–1.08) for stroke.
Characteristics of the two cohorts. Of the 1,265 non-
demented participants, 963 were cognitively intact and 302
had MCI, which constituted the two cohorts for longitudi-
nal analyses. In the cognitively intact cohort, 56 subjects
(5.8%) had diabetes, and 30 (3.1%) had pre-diabetes (Table
1). In the MCI cohort, 18 (6.0%) subjects had diabetes, and
16 (5.3%) were ascertained as having pre-diabetes. Among
the 34 MCI subjects with diabetes or pre-diabetes, 27
(79.4%) were classiﬁed as oCIND, and 7 (20.6%) had aMCI
(Table 2).
Diabetes and MCI in the cognitively intact cohort. In
the cognitively intact cohort, during the 9-year follow-up
(4,656 person-years; mean per person  4.8 years; maxi-
mum  10.5 years), 182 participants developed MCI,
including 42 aMCI and 140 oCIND. In addition, 212 were
diagnosed with dementia, including 150 AD and 26 VaD.
Table 3 shows the incidence rate standardized by age, sex,
and education, and multi-adjusted HRs of MCI related to
diabetes and pre-diabetes. We found no statistically signif-
icant association of either diabetes or pre-diabetes with
incident MCI and its subgroups, whereas diabetes and
pre-diabetes were signiﬁcantly related to an increased risk
of incident dementia. This association was present even
when adjusting for several potential confounders, includ-
ing APOE and vascular disorders. No interaction with
APOE genotype or other variables was obtained.
Diabetes and dementia in the MCI cohort. In the MCI
cohort, during the same period (1,092 person-years; mean
per person  3.6 years; maximum  10.3 years), 155
subjects developed dementia, including 125 AD and 4 VaD.
Using either standard or time-dependent Cox models, we
found that diabetes and pre-diabetes were associated with
an increased risk of developing dementia and AD in people
with MCI after controlling for possible confounders, in-
cluding APOE and vascular disorders (Table 4). Of the 125
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We further performed stratiﬁed analysis according to MCI
subgroups. Diabetes and pre-diabetes substantially in-
creased the risk of progression from oCIND to dementia
(HR 4.31 [95% CI 1.97–9.42]), but not from aMCI (HR 2.24
[95% CI 0.75–6.71]). However, the statistical power was
limited for these stratiﬁed analyses because of the small
number of people in each subgroup of MCI.
Kaplan-Meier survival analysis in people with MCI
showed that the median time from baseline to dementia
occurrence was 1.83 years (95% CI 2.44–4.24) in people
with diabetes or pre-diabetes, and 5.01 years (95% CI
5.15–6.19) in people without such conditions. Thus, diabe-
tes or pre-diabetes accelerated the progression from MCI
to dementia by an average of 3.18 years (Fig. 2).
Supplementary analyses. Similar results were obtained
when we used only the incident MCI cohort that was
identiﬁed at the ﬁrst follow-up examination (n  94, of
whom 36 developed dementia during the next 6-year
follow-up), and when we repeated the analyses among
participants who survived until the time when dementia
status was determined (n  170, 136 dementia and 115
AD). Further, we performed the analyses by leaving out
the participants with missing values of APOE genotype or
BMI, which produced results that were the same as those
from the initial analysis. Finally, in the MCI cohort, among
TABLE 1
Cognitively intact cohort (n  963): characteristics by diabetes status
Characteristics
Diabetes status at baseline
No Diabetes Pre-diabetes P value
n 877 56 30
Baseline
Age (years) 81.1  4.8 80.7  5.0 81.5  4.8 0.913
Female 656 (74.8) 38 (67.9) 22 (73.3) 0.510
Educational level 8 years 398 (45.4) 17 (30.4) 15 (50.0) 0.076
MMSE score 27.6  1.3 27.2  1.3 27.2  1.4 0.678
SBP (mmHg) 156.0  21.0 161.6  26.7 152.9  18.8 0.024
DBP (mmHg) 81.6  11.0 75.0  9.3 77.1  10.1 0.339
Heart disease 128 (14.6) 25 (44.6) 3 (10.0) 0.001
Stroke 48 (5.5) 5 (8.9) 0 (0.0) 0.223
Antihypertensive drug use 389 (44.4) 33 (58.9) 11 (36.7) 0.068
Random blood glucose (mmol/l) 5.1  0.94 11.7  4.6 8.8  0.8 0.001
Any APOE 4 allele† 184 (21.0) 4 (10.0) 3 (7.1)
BMI† (kg/m
2) 23.5  3.48 24.3  3.44 24.1  3.28 0.204
During 9-year follow-up
Incident dementia 192 (21.9) 13 (23.2) 7 (23.3) 0.274
Incident MCI 170 (20.9) 5 (8.9) 6 (21.2) 0.220
Data are n (%) or means  SD. DBP, diastolic blood pressure; SBP, systolic blood pressure. †The number of subjects with missing values
was 207 for APOE genotype and 94 for BMI.
TABLE 2
MCI cohort (n  302): characteristics by diabetes status
Characteristics
Diabetes status at baseline
No Diabetes Pre-diabetes P value
n 268 18 16
Baseline
MCI subtypes
aMCI 113 (42.2) 2 (12.5) 5 (27.8)
oCIND 155 (57.8) 14 (87.5) 13 (72.2) 0.035
Age (years) 82.1  5.0 83.2  5.3 82.6  5.0 0.633
Female sex 203 (75.7) 14 (77.8) 14 (87.5) 0.555
Educational level 8 years 118 (44.0) 6 (33.3) 4 (25.0) 0.237
MMSE score 24.7  1.7 24.1  1.9 23.8  1.8 0.028
SBP (mmHg) 154.0  22.6 156.9  27.7 150.9  19.9 0.744
DBP (mmHg) 80.5  10.6 80.0  8.6 75.0  9.3 0.127
Heart disease 47 (17.5) 6 (33.3) 2 (12.5) 0.202
Stroke 30 (11.2) 4 (22.2) 0 (0.0) 0.123
Antihypertensive drug use 109 (40.7) 12 (66.7) 8 (50.0) 0.081
Random blood glucose (mmol/l) 5.1  1.0 12.2  4.5 8.6  0.8 0.001
Any APOE 4 allele† 78 (29.1) 5 (27.8) 2 (12.5) 0.296
BMI† (kg/m
2) 23.9  3.8 24.2  4.3 24.0  2.9 0.380
During 9-year follow-up
Incident dementia 137 (51.2) 11 (68.8) 7 (38.9) 0.221
Data are n (%) or means  SD. DBP, diastolic blood pressure; SBP, systolic blood pressure. †The number of subjects with missing values
was 90 for APOE genotype and 64 for BMI.
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(52.9%) developed dementia and 16 (47.1%) died during the
9-year follow-up period. Diabetes and pre-diabetes were
signiﬁcantly associated with elevated mortality (HR 1.75
[95% CI 1.17–2.60]) after adjustment for age, sex, educa-
tion, baseline MMSE score, BMI, APOE genotype, and
vascular disorders.
DISCUSSION
The incidence of dementia is increased in patients with
diabetes by 50–100% compared with people without dia-
betes, as shown by several reports, including those from
our group (2). We are now able to extend these ﬁndings by
showing that diabetes and pre-diabetes increase the risk of
conversion from MCI to dementia. In this large longitudi-
nal study of elderly adults, we found that 1) diabetes and
pre-diabetes substantially accelerate the progression from
MCI to dementia; 2) the risk effect of pre-diabetes on the
progression from MCI to dementia appears stronger than
diabetes; 3) diabetes and pre-diabetes anticipate dementia
occurrence by more than 3 years; and 4) we conﬁrm an
increased risk of dementia, but not of MCI, in subjects
with diabetes or pre-diabetes.
To date, Italian (10) and French (17) population-based
longitudinal studies have examined the role of vascular
risk factors, including diabetes, in the progression of MCI
to dementia, and failed to ﬁnd an association. There are
several reasons for the discrepant ﬁndings. First, as pre-
diabetes was not assessed in these two studies, subjects
with this condition were included in the nondiabetes
group, which might have diluted the effect of diabetes on
dementia risk due to the strong inﬂuence of pre-diabetes
on the progression from MCI to dementia, as shown in our
report. Second, in the two studies, diabetes was identiﬁed
based on fasting blood glucose 7.2 and 7.8 mmol/l,
respectively, which are higher than the WHO criteria of 7.0
mmol/l (29). Finally, in both studies, the follow-up time
was only 3.5 to 4 years, and the populations were younger
than our cohort. As a result, the statistical power of the
two studies may be limited because of the small number of
incident dementia cases.
Findings from brain imaging and neuropathologic stud-
ies support the notion that the increased risk of cognitive
decline and dementia in elderly people with diabetes
reﬂects a dual pathologic process involving both cerebro-
vascular damage and neurodegenerative changes (36–38).
In addition to vascular pathways, several possible patho-
physiologic mechanisms, including hyperglyceamia, insu-
lin resistance, oxidative stress, advanced glycation end
products, and inﬂammatory cytokines, may explain the
effect of glucose deregulation on dementia risk. Recent
genetic studies have found that chromosome 10 contains
the genes for both late-onset AD and type 2 diabetes (39).
Interestingly, a clinicopathologic study suggested that
there may be a shared predisposition for developing
amyloid in both the pancreas and the brain (40). All these
mechanisms may explain the accelerated progression
from MCI to dementia observed in this study. In addition,
in subjects with MCI, cognitive deﬁcits may affect the
ability to manage complex behaviors such as those re-
quired for diabetes self-care (41), which may lead to a
vicious circle. Therefore, an additional increased risk of
TABLE 4
Standardized incidence rates (per 1,000 person-years) and multi-adjusted HR and 95% CI of dementia and Alzheimer disease related
to diabetes and pre-diabetes in the mild cognitive impairment cohort
Exposure status
All dementia (n  155) Alzheimer disease (n  125)
IR (95% CI)* HR (95% CI)† IR (95% CI)* HR (95% CI)†
Baseline diabetes‡
No 135.0 (114.2–159.6) 1.00 (Reference) 104.4 (86.0–126.8) 1.00 (Reference)
Yes (diabetes and pre-diabetes) 232.6 (146.6–369.2) 3.64 (2.05–6.45) 206.8 (126.7–337.5) 3.79 (2.02–7.11)
Pre-diabetes 281.3 (155.8–507.9) 4.96 (2.27–10.84) 225.7 (137.6–475.2) 5.73 (2.43–13.50)
Diabetes 182.9 (87.2–383.7) 2.87 (1.30–6.34) 156.7 (70.4–349.0) 2.83 (1.18–6.78)
Baseline and follow-up diabetes§
Diabetes and pre-diabetes 275.4 (150.2–370.1) 3.89 (1.69–8.32) 239.4 (138.6–330.6) 4.22 (1.57– 9.01)
IR, incidence rates. *Standardized by age, sex, and education. †Adjusted for age, sex, education, baseline MMSE score, follow-up survival
status, BMI, heart disease, stroke, systolic blood pressure, diastolic blood pressure, antihypertensive drug use, APOE genotype. ‡From
standard Cox models. §From time-dependent Cox models.
TABLE 3
Standardized incidence rates (per 1,000 person-years) and multi-adjusted HR and 95% CI of MCI and dementia related to diabetes and
pre-diabetes in the cognitively intact cohort
Exposure status
MCI (n  182) Dementia (n  212)
IR (95% CI)* HR (95% CI)† IR (95% CI)* HR (95% CI)†
Baseline diabetes‡
No 39.6 (34.0–46.1) 1.00 (Reference) 49.6 (43.7–56.3) 1.00 (Reference)
Yes (diabetes and pre-diabetes) 32.7 (18.1–59.0) 1.04 (0.52–2.07) 59.8 (39.7–90.0) 1.82 (1.07–3.10)
Pre-diabetes 40.9 (18.4 to 91.1) 1.07 (0.43–2.67) 52.6 (23.7–94.7) 1.64 (1.02–3.44)
Diabetes 26.3 (10.9–63.1) 1.01 (0.37–2.77) 69.6 (41.9–15.4) 2.10 (1.08–4.07)
Baseline and follow-up diabetes§
Diabetes and pre-diabetes 34.6 (18.9–81.3) 1.06 (0.62–1.81) 72.6 (41.3–86.9) 1.81 (1.19–2.75)
IR, incidence rates. *Standardized by age, sex, and education. †Adjusted for age, sex, education, baseline MMSE score, BMI, heart disease,
stroke, systolic blood pressure, diastolic blood pressure, follow-up survival status, and APOE genotype. ‡From standard Cox models. §From
time-dependent Cox models.
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pected in people with MCI.
The stronger effect of pre-diabetes than diabetes on the
conversion from MCI to dementia may be caused by the
high glycemic level in pre-diabetes that is a commonly
ignored condition. In our study, about 30% of patients with
diabetes had normal random blood glucose level by hypo-
glycemic treatment and dietary control; effective glycemic
control may reduce the risk of dementia in people with
diabetes (20). Further, insulin resistance (hyperinsulin-
emia without hyperglycemia) is stronger in people with
pre-diabetes than those with frank diabetes (42).
A number of studies that evaluated the cognitive func-
tion in patients with diabetes or pre-diabetes have shown
that poor glucose regulation is associated with global
cognitive decline, with impaired verbal memory in partic-
ular, but the evidence for deﬁcits in other cognitive
domains is weak (43). However, a recent prospective
study suggested that diabetes-related cognitive deﬁcits
and MCI may represent different entities that do not
necessarily affect the same domains (44). Another longitu-
dinal study reported that diabetes may be related to
psychomotor slowing, but not to deﬁcits in other cognitive
domains typically involved in MCI (45). Results from our
study showed that diabetes and pre-diabetes were associ-
ated with MCI and its subgroups, neither cross sectionally
nor longitudinally. This is in agreement with an Italian
longitudinal study (10) and a case-control study from the
Mayo Clinic (8). However, the latter study found an
association of MCI with a longer duration and greater
severity of diabetes, and Luchsinger et al. (9) reported a
higher risk of both aMCI and oCIND in diabetic patients in
a population with very high prevalence of diabetes. These
ﬁndings suggest that only severe and longstanding diabe-
tes may be related to MCI. Unfortunately, our study
sample was too small to verify this hypothesis. An alter-
native explanation suggested by van den Berg (46) is the
old age of the study population involved, where the lower
cognitive level at baseline may have masked any additional
impact of diabetes. In other words, the standard MCI
criteria may not be sensitive enough to identify those
people with global cognitive deﬁcits due to diabetes (16).
Finally, another possibility is that in very old people,
diabetes and pre-diabetes may accelerate the process of
dementia so rapidly that a possible association between
diabetes and MCI cannot be detected when follow-up
examinations are carried out with intervals longer than 1
year.
The main strengths of our study are the population-
based cohort study, the long-term prospective study de-
sign, and the assessment of diabetes at baseline and each
follow-up examination. However, some limitations should
be noted. First, we used random blood glucose to deﬁne
diabetes and pre-diabetes, which might result in an atten-
uation of the associations. However, the prevalence of
diabetes in our study population (8.9%) is comparable with
those reported from an elderly Swedish population (47).
Second, as there are no speciﬁc recommended tools to
diagnose MCI, the operationalization of the criteria may
differ slightly from those in other studies. In addition,
prevalent MCI cases were included in the MCI cohort,
which might contain persons with long-term cognitive
impairment that remains stable over time. However, sim-
ilar results were obtained when the incident MCI cohort
identiﬁed at ﬁrst follow-up examination was used. Third,
as the Kungsholmen Project is based on an elderly popu-
lation (the mean age was 82 years at baseline), the
dropouts from the screening phase to the third follow-up
were mainly because of death (48). Diabetes, MCI, and
dementia are all associated with elevated mortality
(20,49), which may lead to an underestimation of the
strength of the diabetes-dementia or diabetes-MCI associ-
ation due to selective survival. Thus, caution is needed
when generalizing our ﬁndings to younger populations.
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FIG. 2. Cumulative hazard for the progression from MCI to dementia by diabetes status in the MCI cohort (adjusted for age, sex, and education).
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basis. However, the clinical assessment for dementia was
comprehensive and validated in a previous study (22).
Although neuroimaging data may help detect vascular
lesions in the brain, it is difﬁcult to determine the signiﬁ-
cance of these lesions, as coexistence of AD-related patho-
logic changes and vascular lesions in the brain is very
common in late life (50).
In summary, our results provide further support for the
important role of diabetes and pre-diabetes in dementia,
and highlight the need to control diabetes and detect
pre-diabetes to prevent or postpone dementia in people
with MCI. Our ﬁndings underline the importance of regu-
larly monitoring cognitive function in people with diabetes
and pre-diabetes. The lack of association between diabe-
tes and the risk of MCI in our study suggests that diabetes
may lead to dementia bypassing MCI or shortening the
MCI phase in elderly people.
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